IMM2505

N/A

Report date: 2023/02/13 17:54:04

Base Information

Drug NameIMM2505
Drug Alias NameIMM2505IMM-2505
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionProgrammed death-ligand 1 blockersCluster of differentiation 47 inhibitors
TargetsProgrammed death-ligand 1Cluster of differentiation 47
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSunHo (China) BioPharmaceutical Co LtdImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Inactive CompaniesSunHo (China) BioPharmaceutical Co Ltd
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A